Scientists test new arsenal against stubborn blood cancer
NCT ID NCT06015880
Summary
This early-stage study is testing a new combination of three drugs for adults with an aggressive type of lymphoma that has come back or not responded to previous treatments. The main goal is to find the safest and most effective dose of these drugs when used together. Researchers will also check if the treatment helps shrink the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Virginia Cancer Center
Charlottesville, Virginia, 22908, United States
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157, United States
Conditions
Explore the condition pages connected to this study.